Tyra Biosciences (TYRA) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.45B and a free-cash-flow yield of -7.6%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 2.7/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Momentum
Rising · +42.8% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-48.0%
How far the last close sits under the highest price of the past five years.
Market cap
$1.45B
Trailing P/E
—
Price / book
3.6
Price / sales
—
FCF yield
-7.6%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.8
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
TYRA earnings
Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.67).
Beat the EPS estimate in 1 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 4, 2026
-$0.69
-$0.64
-7.8%
$0
Q1 2026
May 13, 2026
-$0.64
-$0.59
-8.5%
$0
Q4 2025
Mar 2, 2026
-$0.57
-$0.53
-7.5%
$0
Q3 2025
Nov 5, 2025
-$0.50
-$0.51
+2.0%
$0
TYRA analyst price target
Median target $50.00 from 11 analysts, ranging $29.00 – $59.00.
Nama's AI scorecard currently rates Tyra Biosciences Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does TYRA report earnings?
Tyra Biosciences's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.67.
What is the TYRA price target?
The median analyst price target from 11 analysts is $50.00, with a range of $29.00 – $59.00.
Is TYRA Shariah compliant?
Nama's AAOIFI-style screen reads Tyra Biosciences as Can't Tell. A figure the screen needs is missing, so it can't tell.